Published in Cancer Weekly, January 29th, 2002
The resulting construct, a mutant vaccinia virus devoid of thymidine kinase (TK-) and vaccinia growth factor (VGF-), could be used for therapies targeting rapidly dividing cells, a hallmark of tumor progression.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.